Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
To determine if Visudyne photodynamic therapy (low or very low fluence rate) combined with
intravitreal injections of bevacizumab (Avastin) compared with bevacizumab alone will, with
similar safety and efficacy, delay time to retreatment with bevacizumab after the initial
treatment, in subjects with new wet AMD Hypothesis: PDT in combination with Avastin at either
the low or very low fluence rate will delay time to retreatment and reduce the average number
of treatments required, compared to Avastin alone, but will have a similar safety and
efficacy profile.